

FORM TR-1 BE PART I

1) Status of the notification

Final

2) Issuer

Name GALAPAGOS
Identification number 0466-460-429

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold

4) Notification by

A parent undertaking or a controlling person

5) Persons subject to the notification requirement

Name (& legal form for legal persons)	Address (for legal persons)
Felix Baker	
Julian Baker	
Baker Brothers Life Sciences, L.P.	667 Madison Avenue 21st floor, New York, NY 10065, USA
14159, L.P.	667 Madison Avenue 21st floor, New York, NY 10065, USA
667, L.P.	667 Madison Avenue 21st floor, New York, NY 10065, USA

6) Persons that dispose of, ... voting rights (Only to be filled in if art. 7 of the Law applies)

Name (& legal form for legal persons)	Address (for legal persons)

Please continue entering the information in part II concerning the persons referred to in points 5 and 6

Click

7) Date on which the threshold is crossed

4/14/2014 (DDMMYYYY)

8) Threshold that is crossed (in %)

5

If the holding has fallen below the lowest threshold, you have the option of not filling in point 10

9) Denominator

30,098,837

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Julian Baker	0	0	0	0.00%	0.00%
Felix Baker	0	0	0	0.00%	0.00%
667, L.P.	122,772	111,080	0	0.37%	0.00%
Baker Brothers Life Sciences L.P.	1,560,634	1,358,971	0	4.52%	0.00%
14159, L.P.	36,350	33,263	0	0.11%	0.00%
subtotal	1,722,086	1,503,314		4.99%	
TOTAL		1,503,314		4.99%	

Start with "groups" of holders. Calculate subtotals and then finish with the persons who are "alone".
The totals, subtotals and % will be updated once you have clicked on <CALCULATE>

B) Equivalent financial instruments	After the transaction				
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights
TOTAL		(In relation to all expiration dates)			

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (Voting rights & Equivalent financial instruments)	# of voting rights	% of voting rights
	1,503,314	4.99%

11) Chain of controlled undertakings through which the holding is effectively held, if applicable

Please describe, or join a diagram in attachment

Baker Brothers Life Sciences, L.P. is controlled by Baker Brothers Life Sciences Capital, L.P. (General Partner), which is itself controlled by Baker Brothers Life Sciences Capital (GP), LLC (General Partner), which is itself controlled by Mr. Felix Baker and Mr. Julian Baker (each 50% Managing Members). 14159, L.P. is controlled by 14159 Capital, L.P. (General Partner), which is itself controlled by 14159 Capital (GP), LLC (General Partner), which is itself controlled by Mr. Felix Baker and Mr. Julian Baker (each 50% Managing Members). 667, L.P., is a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of

13) Additional information

A) Convertible bonds and rights to subscribe to voting securities not yet issued					
Holder	Type of financial instrument	Expiration date (DD/MM/YYYY)	Exercise/Conversion period or date	Number	# of voting rights that may be acquired if the instrument is exercised/converted

B) Shares without voting rights	
Holder	Number

C) Remarks

Done at

On (DD/MM/YYYY)

Name & capacity

Mr Felix Baker
Mr Julian Baker
Baker Brothers Life Sciences, L.P., represented by Baker Bros. Advisors LP, Management Company and Investment Advisor, pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P. and not as the general partner, represented by Scott L. Lessing, President
14159 L.P., represented by Baker Bros. Advisors LP, Management Company and Investment Advisor to 14159, L.P., pursuant to the authority granted by 14159 Capital L.P., general partner to 14159, L.P. and not as the general partner, represented by Scott L. Lessing, President
667, L.P., represented by Baker Bros. Advisors, LP, Management Company and Investment Advisor to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner, represented by Scott L. Lessing, President

Signature

Signature

Signature

Signature

Signature

